ViCentra raised $85 million in a Series D financing round led by Innovation Industries to launch its Kaleido 2 insulin patch pump and expand into the U.S. market.

Target Company Overview

ViCentra is a European medical device company revolutionizing insulin delivery systems for diabetes management. The company has recently secured an $85 million Series D financing round, spearheaded by Innovation Industries, a prominent European deeptech venture capital firm. Existing stakeholders including Partners in Equity and Invest-NL also participated, along with continued support from EQT Life Sciences and Health Innovations. This significant funding will enable ViCentra to ramp up manufacturing, launch its next-generation Kaleido 2 patch pump in the European market, and prepare for entry into the U.S. market.

The Kaleido 2 patch pump is distinguished as the smallest, lightest, and most precise insulin pump available, designed with a lifestyle-oriented focus. It offers a discreet and user-friendly experience with customizable aluminum shells in a variety of colors, making it feel more like personal technology rather than a traditional medical device. The innovative patch pump integrates seamlessly with Diabeloop’s self-learning automated insulin delivery algorithm and is compatible with the Dexcom CGM sensor, positioning ViCentra as a leader in modern diabetes care.

Industry Overview in the Netherlands

The global insulin delivery market is experiencing rapid growth, primarily due to the escalating prevalence of diabetes and the demand for medical solutions that marry clinical effectiveness with daily usability. By 2034, the insulin pump market is projected to e